Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio per studiare l'uso di VH3810109 con o senza fostemsavir (FTR) per ridurre le dimensioni e l'attività del serbatoio virale nelle persone che vivono con l'HIV (ENTRANCE)

25 settembre 2026 aggiornato da: ViiV Healthcare

Uno studio di fase 1b esplorativo, multicentrico, randomizzato, per studiare l'impatto della somministrazione di VH38101010109 endovenoso con o senza fostemsavir orale in combinazione con terapia antiretrovirale a base di inibitori integrasi sul serbatoio virale negli adulti che vivono con HIV-1

This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimen (Population 2). The study is designed to include the following phases: Randomized Intervention Phase (Step 1), Analytical Treatment Interruption (ATI) Phase (Step 2), and Follow-up Phase (Step 3).

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

107

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Brussels, Belgio, 1000
        • GSK Investigational Site
    • Oost-Vlaanderen
      • Ghent, Oost-Vlaanderen, Belgio, 9000
        • GSK Investigational Site
    • Capital Region
      • Hvidovre, Capital Region, Danimarca, 2650
        • GSK Investigational Site
    • Central Jutland
      • Aarhus N, Central Jutland, Danimarca, 8200
        • GSK Investigational Site
      • Rotterdam, Olanda, 3015 GD
        • GSK Investigational Site
      • London, Regno Unito, SE1 7EH
        • GSK Investigational Site
      • London, Regno Unito, NW3 2QG
        • GSK Investigational Site
      • London, Regno Unito, W2 1NY
        • GSK Investigational Site
      • Barcelona, Spagna, 08036
        • GSK Investigational Site
      • Barcelona, Spagna, 08035
        • GSK Investigational Site
      • Barcelona, Spagna, 08003
        • GSK Investigational Site
      • Barcelona, Spagna, 8907
        • GSK Investigational Site
      • Barcelona, Spagna, 08026
        • GSK Investigational Site
      • Barcelona, Spagna, 08916
        • GSK Investigational Site
      • Córdoba, Spagna, 14004
        • GSK Investigational Site
      • La Laguna Santa Cruz, Spagna, 38320
        • GSK Investigational Site
      • Madrid, Spagna, 28041
        • GSK Investigational Site
      • Madrid, Spagna, 28040
        • GSK Investigational Site
      • Madrid, Spagna, 28046
        • GSK Investigational Site
      • Madrid, Spagna, 28034
        • GSK Investigational Site
      • Madrid, Spagna, 28031
        • GSK Investigational Site
      • Madrid, Spagna, 28020
        • GSK Investigational Site
      • Palma de Mallorca, Spagna, 07120
        • GSK Investigational Site
      • Palma de Mallorca, Spagna, 7198
        • GSK Investigational Site
      • Seville, Spagna, 41013
        • GSK Investigational Site
      • Valencia, Spagna, 46026
        • GSK Investigational Site
      • Valencia, Spagna, 46014
        • GSK Investigational Site
    • Madrid
      • Pozuelo de Alarcón, Madrid, Spagna, 28224
        • GSK Investigational Site
    • California
      • Bakersfield, California, Stati Uniti, 93309
        • GSK Investigational Site
      • San Diego, California, Stati Uniti, 92103
        • GSK Investigational Site
    • Florida
      • Ft. Pierce, Florida, Stati Uniti, 34982-7148
        • GSK Investigational Site
      • Orlando, Florida, Stati Uniti, 32803-1851
        • GSK Investigational Site
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60611
        • GSK Investigational Site
    • Missouri
      • Kansas City, Missouri, Stati Uniti, 64111
        • GSK Investigational Site
      • St Louis, Missouri, Stati Uniti, 63110
        • GSK Investigational Site
    • New York
      • New York, New York, Stati Uniti, 10032
        • GSK Investigational Site
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45267
        • GSK Investigational Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • GSK Investigational Site
      • Pittsburgh, Pennsylvania, Stati Uniti, 15213
        • GSK Investigational Site
    • Texas
      • Dallas, Texas, Stati Uniti, 75246-2004
        • GSK Investigational Site
      • Dallas, Texas, Stati Uniti, 75208-4599
        • GSK Investigational Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 70 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

AGE

• Age between 18 years and 70 years old at the time of obtaining informed consent.

SEX AND GENDER • Persons of any sex or gender are eligible. Note: Participants of childbearing potential (POCBP) are eligible to participate if not pregnant, not lactating, and agreeing to adhere to study requirements for use of contraception and pregnancy avoidance.

PARTICIPANT KEY CHARACTERISTICS • Participant has a documented diagnosis of HIV-1 infection. Note: Participants in Population 1 must have a documented positive HIV antibody result available for Screening.

Population 1 only:

  • Plasma HIV-1 RNA >=2000 copies/milliliter (c/mL) at Screening.
  • CD4+ T cell count >=300 cells/microliter (μL) at Screening.
  • Antiretroviral treatment naïve, defined as no exposure to ART after a diagnosis of HIV-1 infection, prior to enrollment.

Population 2 only:

  • Participant is stably virologically suppressed (plasma HIV-1 RNA <50 c/mL).
  • Documented evidence of uninterrupted treatment with oral non-boosted INSTI-based ART for at least 6 months prior to Screening, as well as uninterrupted treatment with ART (any guideline-recommended oral regimen) for at least 24 months prior to Screening.
  • CD4+ T cell count >=450 cells/μL at Screening.

WEIGHT

• Body weight >=50 kg to <=115 kg.

INFORMED CONSENT • Participant is capable of giving written informed consent, which includes adherence to the requirements and restrictions listed in the consent form and in the protocol.

Exclusion Criteria:

CONCURRENT MEDICAL CONDITIONS & MEDICAL HISTORY

  • Participant is pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study.
  • Participant has documented diagnosis of HIV-2 infection.
  • Participant is known to have acquired HIV via perinatal transmission.
  • Any evidence of a current or known past Center for Disease Control and Prevention (CDC) Stage 3 disease.
  • Any ongoing malignancy or history of systemic cancers, such as Kaposi's sarcoma and lymphoma, or other virus-associated malignancies.
  • Ongoing or clinically relevant pancreatitis.
  • Current HIV-related kidney disease.
  • History of or active HIV-associated dementia or progressive multifocal leukoencephalopathy.

CARDIAC & CARDIOVASCULAR CONDITIONS

  • Participants who are at clinically significant risk of cardiovascular disease.
  • Ongoing or any lifetime history of clinically significant cardiovascular or cardiac disease.
  • Confirmed QTcF value outside normal range at Screening or Day 1.

HEPATIC CONDITIONS

  • History of clinically relevant hepatitis in the 6 months prior to Screening.
  • Participants with severe hepatic impairment.
  • Advanced MAFLD and advanced non-alcoholic steatohepatitis, if evidence for substantial fibrosis (fibrosis score ≥F2) or evidence of cirrhosis.
  • Unstable liver disease.
  • History of liver cirrhosis with or without hepatitis viral co-infection.

NEUROPSYCHIATRIC CONDITIONS • Participants who pose a significant suicide risk.

LABORATORY DIAGNOSTIC ASSESSMENTS

  • Participants who are experiencing (Population 1) or are known to have initiated ART during (Population 2) acute HIV infection.
  • Any verified Grade 4 laboratory abnormality at Screening, excluding asymptomatic elevations of lipids or CPK.
  • Alanine transferase (ALT) >=3 times the upper limit of normal (ULN) at Screening.
  • Estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m^2.
  • Hemoglobin >=Grade 2 at Screening.
  • Platelets >=Grade 2 at Screening.
  • Absolute Neutrophil Count (ANC) ≥Grade 2 at Screening.
  • Any acute abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's inclusion in an interventional clinical study.

Population 2 only:

• Two or more plasma HIV-1 RNA results >=50 c/mL in the 18 months prior to Screening.

INFECTIOUS DISEASES

  • Active hepatitis B virus (HBV) co-infection.
  • Active hepatitis C virus (HCV) co-infection.
  • Participant has untreated syphilis before enrolment.
  • Known history of active Mycobacterium TB disease (regardless of treatment status).

ANTIRETROVIRAL RESISTANCE • Known major resistance-associated mutations to second-generation INSTIs or to antiretroviral (ARV) agents from 2 or more drug classes.

PRIOR AND CONCOMITANT MEDICATIONS

  • Prior use of any of the following agents:

    - long-acting ARVs (any dose in the past 24 months or within 5 half-lives [whichever is longer])

    - FTR (any lifetime use)

    - HIV-1 immunotherapeutic vaccines or prophylactic vaccines (any lifetime use)

    - HIV-1 monoclonal antibody therapy (any lifetime use).

  • Prior receipt of any approved or experimental non-HIV vaccination within 2 weeks prior to study enrolment.

  • History of systemic corticosteroids, immunosuppressive anti-cancer, interleukins, systemic interferons, or systemic chemotherapy, within 6 months prior to Screening.

  • Participant has received an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent (whichever is longer), prior to enrolment.

  • Treatment with any of the following agents within 30 days of enrolment:

    - radiation therapy

    • cytotoxic chemotherapeutic agents
    • anti-tuberculosis therapy
    • immunomodulators that alter immune responses such as chronic systemic corticosteroids, interleukins, or interferons.
  • Participant is receiving any protocol-defined prohibited medication and is unwilling or unable to switch to an alternate medication. Prohibited medications must be stopped within 7 days (or 14 days if the drug is a potential CYP3A4 enzyme inducer) or 5 half-lives (whichever is longer), prior to enrolment.

Population 1 only:

• Known use of PrEP or PEP within <30 days (for oral agents) or <52 weeks (for LA parenteral agents) of HIV-1 diagnosis. Participants with a documented seronegative result >=30 days after the last dose of oral PrEP or PEP (or >=52 weeks after the last dose of LA PrEP) are not excluded.

Population 2 only:

• Current use of NNRTI-containing ART.

OTHER EXCLUSIONS

  • History or presence of allergy or intolerance to the study drugs or their components or drugs of their class, or a history of drug or other allergy that contraindicates study participation.
  • Any condition which may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive study drugs.
  • Any pre-existing physical or mental condition (including substance use disorder) which, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
  • Participant is currently participating in, or anticipates being selected for, any other interventional study.
  • Participant is known or suspected to be an HIV long-term non-progressor or elite controller, based on historical off-treatment plasma HIV-1 RNA results.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Participants receiving SOC INSTI-based ART in Randomized Intervention Phase (Step 1)

A SOC INSTI-based ART regimen will be administered.

Sperimentale: Participants receiving SOC INSTI-based ART+VH3810109 in Randomized Intervention Phase (Step 1)

A SOC INSTI-based ART regimen will be administered.

VH3810109 will be administered.

Altri nomi:
  • Lotivibart (LVB)
Sperimentale: Participants receiving SOC INSTI-based ART+VH3810109+FTR in Randomized Intervention Phase (Step 1)

A SOC INSTI-based ART regimen will be administered.

VH3810109 will be administered.

Altri nomi:
  • Lotivibart (LVB)

Fostemsavir will be administered.

Altri nomi:
  • Rukobia
Sperimentale: Participants receiving VH3810109 in ATI Phase (Step 2)

VH3810109 will be administered.

Altri nomi:
  • Lotivibart (LVB)

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
Randomized Intervention Phase (Step 1): Change from baseline in cell-associated HIV-1 RNA transcripts per million cluster of differentiation 4 (CD4+) T cells
Lasso di tempo: From Baseline (Day 1) to Month 12
From Baseline (Day 1) to Month 12

Misure di risultato secondarie

Misura del risultato
Lasso di tempo
Randomized Intervention Phase (Step 1): Change from baseline in total, intact, and defective proviral HIV-1 DNA per million CD4+ T cells
Lasso di tempo: From Baseline (Day 1) to Month 12
From Baseline (Day 1) to Month 12
Randomized Intervention Phase (Step 1): Absolute change in cell-associated HIV-1 RNA/proviral DNA ratios in CD4+ T cells
Lasso di tempo: From Baseline (Day 1) to Month 12
From Baseline (Day 1) to Month 12
Randomized Intervention Phase (Step 1): Absolute values for HIV-1-specific CD8+ T cell count
Lasso di tempo: From Baseline (Day 1) to Month 12
From Baseline (Day 1) to Month 12
Randomized Intervention Phase (Step 1): Change from baseline in HIV-1-specific CD8+ T cell count
Lasso di tempo: From Baseline (Day 1) to Month 12
From Baseline (Day 1) to Month 12
Randomized Intervention Phase (Step 1): Number of participants with Grade 3 and Grade 4 adverse events (AEs)
Lasso di tempo: From Baseline (Day 1) to Month 15
From Baseline (Day 1) to Month 15
Randomized Intervention Phase (Step 1): Number of participants with serious adverse events (SAEs), deaths and AEs leading to discontinuation of study intervention
Lasso di tempo: From Baseline (Day 1) to Month 15
From Baseline (Day 1) to Month 15
ATI Phase (Step 2): Time to ART restart
Lasso di tempo: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
ATI Phase (Step 2): Number of participants with Grade 3 and Grade 4 AEs
Lasso di tempo: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
ATI Phase (Step 2): Number of participants with SAEs and deaths
Lasso di tempo: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
ATI Phase (Step 2): Number of participants with disease progression (HIV-associated conditions, acquired immunodeficiency syndrome [AIDS] and death)
Lasso di tempo: From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)
From Day 1A to Week 24A (ATI Phase Alpha) and Week 48A (ATI Phase Gamma)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

10 luglio 2025

Completamento primario (Stimato)

22 gennaio 2027

Completamento dello studio (Stimato)

6 settembre 2028

Date di iscrizione allo studio

Primo inviato

26 giugno 2025

Primo inviato che soddisfa i criteri di controllo qualità

26 giugno 2025

Primo Inserito (Effettivo)

8 luglio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

28 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

25 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 221794
  • 2025-520629-19-00 (Altro identificatore: EU CT Number)
  • 2025 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf

Periodo di condivisione IPD

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Criteri di accesso alla condivisione IPD

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .